Home
Search
Study Topics
Glossary
|
Study 14 of 211 for search of: | "Hemoglobinopathies" |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00000595 |
To determine whether deferoxamine prevented the complications of transfusional iron overload.
Condition | Intervention | Phase |
---|---|---|
Anemia (Iron-Loading) Beta-Thalassemia Hematologic Diseases Hemoglobinopathies Thalassemia Iron Overload Hemochromatosis |
Drug: deferoxamine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Study Start Date: | January 1978 |
BACKGROUND:
The prognosis of congenital or long-term anemia was formerly limited by the complications of blood transfusion, splenectomy, or infection, problems now largely overcome by sophisticated clinical care. Lifespan is now determined by the rate of myocardial iron deposition, with death occurring from cardiac failure or arrhythmia, usually between the ages of 15 and 25. Endocrine complications and hepatic enlargement are also evident by this age. Deferoxamine increases urinary iron excretion and is the only chelator currently available for chronic administration. Daily administration of deferoxamine results in negative iron balance in most patients by the age of 10; this study was designed to determine whether the onset of cardiac complications was delayed and life prolonged by iron removal.
This trial began in 1978. Its forerunner was a study involving both deferoxamine and ascorbic acid. Although ascorbic acid promotes iron removal, its administration was followed by cardiac deterioration in several patients. In this study, patients receiving subcutaneous deferoxamine were randomized to receive either ascorbic acid or placebo, thereby providing a controlled test of this agent in treatment of iron overload. Sixty-five patients with homozygous beta-thalassemia participated in the long-term chelation trial. Of these, 49 were randomized to the ascorbic acid trial.
Several noninvasive techniques have been developed to evaluate organ function in iron-overloaded patients, thereby facilitating the assessment of chelation therapy. These techniques included chest x-rays, electrocardiograms, echocardiograms, and 24-hour Holter monitoring to assess cardiac function. Liver function was evaluated by standard liver function tests, CAT scan, and live biopsy. During the last six years of the study, hepatic iron stores were measured magnetically with a dual channel superconducting quantum-interference susceptomer. Endocrine function was also assessed by standard tests.
DESIGN NARRATIVE:
All patients received subcutaneous deferoxamine and iron removal was determined by measurement of serum ferritin and periodic non-invasive measurements of liver iron concentration. Clinical status was evaluated by non-invasive testing of cardiac and endocrine function.
Ages Eligible for Study: | 5 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Males and females, 5 years or older, with transfusional hemochromatosis.
Study ID Numbers: | 401 |
Study First Received: | October 27, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000595 |
Health Authority: | United States: Federal Government |
Metabolic Diseases Hematologic Diseases Beta-thalassemia Anemia Hemochromatosis, type 3 Anemia, Hemolytic Iron Metabolism Disorders Thalassemia Anemia, Hemolytic, Congenital Metabolism, Inborn Errors |
Thalassemia minor Genetic Diseases, Inborn Beta-Thalassemia Hemoglobinopathies Hemochromatosis Iron Overload Metabolic disorder Hemoglobinopathy Iron Deferoxamine |
Molecular Mechanisms of Pharmacological Action Iron Chelating Agents Chelating Agents |
Metal Metabolism, Inborn Errors Pharmacologic Actions Siderophores |